Ainos News

Market Mover | Ainos Shares Soar 30% After the Company Reports Progress in Clinical Trials of Ainos Flora Testing Device

The company announced progress in the clinical trials of its Ainos Flora volatile organic compound point-of-care testing device.

moomoo NewsJun 14 09:40 ET · Movers

Ainos AIMD AI Ainos Flora Leverage; Bio-Path BPTH Phase 2 Data

BioPharmCatalystJun 14 08:25 ET

Express News | Ainos Inc - Clinical Trials for AI Nose-Powered Ainos Flora Device Moves Forward With 75Meaningful Case Results

ReutersJun 14 08:09 ET

Express News | Ainos Inc - Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by Nvidia Cuda

ReutersJun 14 08:09 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersAinos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards

BenzingaJun 14 08:06 ET

Express News | Ainos Inc Files for Mixed Shelf of up to $200 Mln – SEC Filing

ReutersMay 31 16:40 ET

Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment

Ainos (AIMD) said Wednesday it is set to begin a clinical trial of a potential Veldona-based treatment for chronic gingivostomatitis in cats. Ainos described feline chronic gingivostomatitis as a chro

MT NewswiresMay 15 11:36 ET

Ainos To Initiate Clinical Study Of New VELDONA-Based Animal Drug, Expanding Potential Market

Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synt

BenzingaMay 15 08:18 ET

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

Current research suggests that FCGS results from multiple factors, including dental diseases, viral and bacterial pathogens, and environmental conditions, with a reported prevalence ranging between 0.7% and 12%.

AccesswireMay 15 08:15 ET

Ainos Q1 2024 EPS $(0.57) Up From $(0.63) YoY; Revenue $20.729K Down From $49.164K YoY

Ainos Q1 2024 EPS $(0.57) Up From $(0.63) YoY; Revenue $20.729K Down From $49.164K YoY

BenzingaMay 13 16:30 ET

10-Q: Quarterly report

SEC announcementMay 13 16:15 ET · Announcements

Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729

04:13 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729

MT NewswiresMay 13 16:13 ET

Express News | ASE Technology Holding Co., Ltd - May Consider, Formulate, Discuss and Seek to Cause Ainos Inc to Implement Various Plans or Proposals

ReutersMay 8 06:24 ET

Express News | ASE Technology Holding Co., Ltd Reports 27.4% Stake in Ainos Inc as of May 3 - SEC Filing

ReutersMay 8 06:22 ET

Express News | Ainos Inc Files Prospectus Relates To Resale, From Time To Time, Of Up To 4.43M Shares Of Common Stock By Selling Stockholders

Moomoo 24/7Apr 8 16:10 ET

Express News | On Mar 15, Ainos Inc Appointed Christopher Hsin-liang Lee As CFO

Moomoo 24/7Mar 19 17:05 ET

Express News | Ainos Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in FY23 Revenue Results

Moomoo 24/7Mar 11 11:29 ET

Lexicon Pharmaceuticals, Mesoblast, Ventyx Biosciences Among Healthcare Movers

Seeking AlphaMar 11 10:00 ET

Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street

US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser

MT NewswiresMar 11 09:49 ET

Top Premarket Decliners

Ainos (AIMD) shares decreased nearly 20% after the company reported Friday lower annual revenue for 2023. CERo Therapeutics (CERO) shares were down 14%, shaving Friday's gains. Lytus Technologies (LYT

MT NewswiresMar 11 08:57 ET